Floatz logo

Turalio

Precursor Cell Lymphoblastic Leukemia-Lymphoma

National Cancer Institute (NCI)Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Precursor Cell Lymphoblastic Leukemia-Lymphoma cohort.

Asset / SponsorPhaseRating
LIDOCAINE
CAMC Health System
Phase 4BB
DEXAMETHASONE
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
ETOPOSIDE
Asan Medical Center
Phase 2B
DARATUMUMAB
Janssen Research & Development, LLC
Phase 2B

View all 33 →

Same molecule, other indications

Turalio is also rated in:

acute promyelocytic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
sarcomaDormant
C
Indicative ·
39 / 100
View asset →
plexiform neurofibromaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →